CSL112

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
0120132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
OBJECTIVE CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early… (More)
Is this relevant?
2017
2017
 
Is this relevant?
2016
2016
BACKGROUND Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated… (More)
Is this relevant?
2016
2016
RATIONALE CSL112, human apolipoprotein A-I (apoA-I) reconstituted with phosphatidylcholine, is known to cause a dramatic rise in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table II
Is this relevant?
2016
2016
BACKGROUND Despite aggressive pharmacotherapy and stenting, there is a residual risk of major adverse cardiovascular events among… (More)
Is this relevant?
2015
2015
BACKGROUND CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events… (More)
Is this relevant?
2014
2014
CSL112 is apoA-I purified from human plasma and reconstituted with phosphatidylcholine (PC) to form high-density lipoprotein (HDL… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
OBJECTIVE The ability of high-density lipoprotein (HDL) to remove cholesterol from atherosclerotic plaque is thought to underlie… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?